摘要 |
The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson- related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. |
申请人 |
NOVARTIS AG;FURET, PASCAL;GROTZFELD, ROBERT MARTIN;JONES, DARRYL BRYNLEY;MANLEY, PAUL;MARZINZIK, ANDREAS;PELLE, XAVIER FRANCOIS ANDRE;SALEM, BAHAA;SCHOEPFER, JOSEPH |
发明人 |
FURET, PASCAL;GROTZFELD, ROBERT MARTIN;JONES, DARRYL BRYNLEY;MANLEY, PAUL;MARZINZIK, ANDREAS;PELLE, XAVIER FRANCOIS ANDRE;SALEM, BAHAA;SCHOEPFER, JOSEPH |